OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
GLP-1 receptor agonists, SGLT2 inhibitors and noncardiovascular mortality in type 2 diabetes: Insights from a meta-analysis
Mainak Banerjee, Rimesh Pal, Indira Maisnam, et al.
Diabetes & Metabolic Syndrome Clinical Research & Reviews (2024) Vol. 18, Iss. 1, pp. 102943-102943
Closed Access | Times Cited: 7
Mainak Banerjee, Rimesh Pal, Indira Maisnam, et al.
Diabetes & Metabolic Syndrome Clinical Research & Reviews (2024) Vol. 18, Iss. 1, pp. 102943-102943
Closed Access | Times Cited: 7
Showing 7 citing articles:
SGLT2 inhibition and three urological cancers: Up‐to‐date results
Lede Lin, Ning Kang, Liyuan Xiang, et al.
Diabetes/Metabolism Research and Reviews (2024) Vol. 40, Iss. 3
Closed Access | Times Cited: 9
Lede Lin, Ning Kang, Liyuan Xiang, et al.
Diabetes/Metabolism Research and Reviews (2024) Vol. 40, Iss. 3
Closed Access | Times Cited: 9
Association of NAFLD/NASH, and MAFLD/MASLD with chronic kidney disease: an updated narrative review
Amedeo Lonardo
Metabolism and Target Organ Damage (2024) Vol. 4, Iss. 2
Open Access | Times Cited: 9
Amedeo Lonardo
Metabolism and Target Organ Damage (2024) Vol. 4, Iss. 2
Open Access | Times Cited: 9
The pharmacodynamics-based prophylactic benefits of GLP-1 receptor agonists and SGLT2 inhibitors on neurodegenerative diseases: evidence from a network meta-analysis
Ping‐Tao Tseng, Bing‐Yan Zeng, Chih-Wei Hsu, et al.
BMC Medicine (2025) Vol. 23, Iss. 1
Open Access | Times Cited: 1
Ping‐Tao Tseng, Bing‐Yan Zeng, Chih-Wei Hsu, et al.
BMC Medicine (2025) Vol. 23, Iss. 1
Open Access | Times Cited: 1
Evidence of phenolic compounds as modulators of ChREBP and NRF2 in type 2 diabetes: a review of their potential for drug development
Carina Proença, M. Graça Lobo, Ana T. Rufino, et al.
Phytochemistry Reviews (2025)
Closed Access
Carina Proença, M. Graça Lobo, Ana T. Rufino, et al.
Phytochemistry Reviews (2025)
Closed Access
Highlights of the current issue
Ningjian Wang, Anoop Misra
Diabetes & Metabolic Syndrome Clinical Research & Reviews (2024) Vol. 18, Iss. 1, pp. 102948-102948
Open Access
Ningjian Wang, Anoop Misra
Diabetes & Metabolic Syndrome Clinical Research & Reviews (2024) Vol. 18, Iss. 1, pp. 102948-102948
Open Access
Sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide 1 receptor agonists and cancer mortality. A real-world registry
David García‐Vega, Sergio Cinza‐Sanjurjo, Carlos Tilves-Bellas, et al.
Revista Española de Cardiología (English Edition) (2024)
Open Access
David García‐Vega, Sergio Cinza‐Sanjurjo, Carlos Tilves-Bellas, et al.
Revista Española de Cardiología (English Edition) (2024)
Open Access
The Promising Potency of Sodium–Glucose Cotransporter 2 Inhibitors in the Prevention of and as Treatment for Cognitive Impairment Among Type 2 Diabetes Patients
Yibin Zhang, Xiao-xing Liao, Jialu Xu, et al.
Biomedicines (2024) Vol. 12, Iss. 12, pp. 2783-2783
Open Access
Yibin Zhang, Xiao-xing Liao, Jialu Xu, et al.
Biomedicines (2024) Vol. 12, Iss. 12, pp. 2783-2783
Open Access
